Main characteristics of the included trials
| Study | Type | Treatment arms | Sample size | Definition of ISR | Follow-up, months | DAPT, months | Definition of MACE | |||
| Angiographic | Clinical | DCB | DES | |||||||
| TIS | BMS | SP PCB | PE EES | 68/68 | ≥50% DS | 12 | 12 | 3 | 6–12 | Death, any MI and TVR |
| RIBS IV | DES | SP PCB | XP EES | 154/155 | ≥50% DS | 9 | 12 | 3 | 12 | Death, MI and TLR |
| SEDUCE | BMS | SP PCB | XP EES | 25/25 | >70% DS | 9 | 12 | n/a | n/a | n/a |
| RIBS V | BMS | SP PCB | XP EES | 95/94 | ≥50% DS | 9 | 36 | 3 | 12 | Death, MI and TLR |
| BIOLUX RCT | Both | PL PCB | Orsiro SES | 157/72 | n/a | 6 | 12 | n/a | n/a | Cardiac death, MI and TLR |
BMS, bare-metal stents; DAPT, dual antiplatelet therapy; DCB, drug-coated balloon; DES, drug -eluting stents; DS, diameter stenosis; ISR, in-stent restenosis; MACE, major adverse cardiac events; MI, myocardial infarction; n/a, not available; PE EES, Promus Element everolimus-eluting stents; PL PCB, Pantera Lux paclitaxel-coated balloon; RCT, randomised controlled trial; SEDUCE, Safety and Efficacy of a Drug eIUting balloon in Coronary artery rEstenosis; SES, sirolimus-eluting balloon; SP PCB, SeQuent Please paclitaxel-coated balloon; TLR, target lesion revascularisation; TVR, target vessel revascularisation; XP EES, Xience Prime everolimus-eluting stent.